Results 101 to 110 of about 171,176 (147)

Effects of Low-Sodium Oxybate on 24-Hour Total Sleep Time: Data From a Phase 3 Clinical Study in Adults With Idiopathic Hypersomnia (P5-13.001)

Neurology, 2023
Anne Marie Morse, Abby Chen, Teresa Steininger, Wayne Macfadden   +3 more
openaire   +2 more sources

Effectiveness and Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia: Top-line Results From the Phase 4 DUET Study (P10-2.008)

Neurology
Logan Schneider, David Plante, Deborah A. Nichols, Teresa Steininger, Douglas S. Fuller, M. Todd Kirby, Sarah Akerman, Jessica Alexander, Chad Ruoff, Alyssa Cairns   +9 more
openaire   +2 more sources

1009 Effectiveness and Satisfaction with Low-Sodium Oxybate as Described by Adults Living with Narcolepsy: LYRICAL Survey & Interview Findings

SLEEPJ
Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat cataplexy or excessive daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy.
C. Drachenberg, M. Farrell, Jennifer D’Souza, Emily Kim, Meaghan Lawrence, Christina Graham, M. Whalen, Jessica K Alexander, Silky Beaty, S. Markt, L. Herpel   +10 more
semanticscholar   +1 more source

Efficacy, safety, and tolerability of low sodium oxybate for nocturnal cluster headache attacks in chronic cluster headache: protocol for a phase II randomized, double-blind, placebo-controlled, trial (SUNCET).

Pain Management
BACKGROUND Cluster headache presents with severe headache attacks that typically occur during sleep. This study aims to evaluate the efficacy, tolerability, and safety of low sodium oxybate (LXB), a sleep-deepening drug, for nocturnal attacks in chronic ...
M. van Liefland, P. V. van Tilborg, M. Szmukała, Z. Zhang, C. Kramers, G. Lammers, R. Khatami, R. Fronczek   +7 more
semanticscholar   +1 more source

Efficacy of Low-sodium Oxybate by Baseline Sleep Inertia in a Phase 3 Clinical Study in Participants with Idiopathic Hypersomnia (P10-9.003)

Neurology
Michael Thorpy, Douglas Fuller, Marisa Whalen, Wayne Macfadden, Yves Dauvilliers   +4 more
openaire   +2 more sources

1011 Individualized Dosing with Low-Sodium Oxybate in Idiopathic Hypersomnia: Patient Voices from LYRICAL

SLEEPJ
In the US, low-sodium oxybate (LXB; Xywav®) is approved by the Food and Drug Administration for the treatment of idiopathic hypersomnia (IH) in adults, and has the option for individualized dosing.
C. Drachenberg, M. Farrell, Jennifer D’Souza, Emily Kim, Meaghan Lawrence, Christina Graham, M. Whalen, Jessica K Alexander, Silky Beaty, S. Markt, L. Herpel   +10 more
semanticscholar   +1 more source

Effectiveness and Optimization of Low-sodium Oxybate in Participants with Narcolepsy Switching from Sodium Oxybate: Final Data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav (SEGUE) Study (P10-9.001)

Neurology
Wayne Macfadden, Eileen Leary, Craig Pfister, Douglas Fuller   +3 more
openaire   +2 more sources

1012 Individualized Dosing with Low-Sodium Oxybate in Narcolepsy: Patient Voices from LYRICAL

SLEEPJ
In the US, low-sodium oxybate (LXB; Xywav®) is approved for treating cataplexy or excessive daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy and has the option for individualized dosing.
C. Drachenberg, M. Farrell, Jennifer D’Souza, Emily Kim, Meaghan Lawrence, Christina Graham, M. Whalen, Jessica K Alexander, Silky Beaty, S. Markt, L. Herpel   +10 more
semanticscholar   +1 more source

C21-02 Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia, With or Without Comorbid Obstructive Sleep Apnea: A Post Hoc Analysis of the Duet Study

American Journal of Respiratory and Critical Care Medicine
Low-sodium oxybate (LXB; Xywav®) is FDA approved for treatment of cataplexy and excessive daytime sleepiness (EDS) in people ≥7 years of age with narcolepsy, and for idiopathic hypersomnia in adults.
C. Ruoff, R. Sangal, D. Nichols, T. Steininger, J. Dai, A. Cairns, M. Whalen, L. Herpel   +7 more
semanticscholar   +1 more source

0755 Patient-Reported Improvement in Hypersomnolence Measures in Participants with Narcolepsy Taking >9 Gram Dosage of Low-Sodium Oxybate in the DUET Study

SLEEPJ
Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment; NCT05875974) was the first study to evaluate effectiveness/safety of low-sodium oxybate (LXB; Xywav®) >9 g/night (outside the recommended range: 6–9 g/night ...
Richard K. Bogan, C. Ruoff, D. Plante, D. Nichols, T. Steininger, Jing Dai, Thomas Measey, M. Whalen, A. Cairns, Logan D Schneider, J. Simmons   +10 more
semanticscholar   +1 more source